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New palladium(II) and platinum(II) 5,5-
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dipyridylamine: synthesis, structures, DNA 
binding, molecular docking, cellular uptake, 
antioxidant activity and cytotoxicity 
Ceyda Icsel,a Veysel T. Yilmaz,*a Yunus Kaya,a Hale Samli,b William T. A. 
Harrisonc and Orhan Buyukgungord  
Novel palladium(II) and platinum(II) complexes of 5,5-diethylbarbiturate (barb) with 2-phenylpyridine 
(Hppy), 2,2’-bipyridine (bpy) and 2,2’-dipyridylamine (dpya) have been prepared and characterized by 
elemental analysis, IR, UV-Vis, NMR and ESI-MS. Single-crystal diffraction measurements show that 
complex 1 consists of binuclear [Pd2(µ-barb-κN,O)2(ppy-κN,C)2]  moieties, while complexes 3–5 are 
mononuclear, [M(barb-κN)2(L-κN,N’)] (L = bpy or dpya). 6 has a composition of [Pt(dpya-
κN,N’)2][Ag(barb-κN)2]2·4H2O and 2 was assumed to have a structure of [Pt(barb-κN)(Hppy-κN)(ppy-
κN,C)]·3H2O. The complexes were found to exhibit significant DNA binding affinity by a non-covalent 
binding mode, in accordance with molecular docking studies. In addition, complexes 1 and 2 displayed 
strong binding with supercoiled pUC19 plasmid DNA. Cellular uptake studies were performed to assess 
the subcellular localization of the selected complexes. A moderate radical scavenging activity of 1 and 2 
was confirmed by DPPH and ABTS tests. Complexes 1, 2, and 5 showed selectivity against HT-29 (colon) 
cell line.  
Introduction 
Since the discovery of anticancer activity of cisplatin, cis-
[PtCl2(NH3)2], in the 1970’s, metal complexes have gained a 
progressively increasing interest in medicinal chemistry.1-5 The 
more effective and less toxic second- and third-generation 
platinum-based anticancer agents, carboplatin and oxaliplatin 
with the leaving groups of 1,1-cyclobutanedicarboxylate and 
oxalate, respectively, were successfully tested and went on to 
achieve worldwide clinical acceptance.6,7 The presence of 
chloride anions as leaving groups promotes DNA-binding 
ability of cisplatin via covalent bonding, while the carboxylate 
anions in carboplatin and oxaliplatin  improve the water 
solubility and the stability of these complexes.8-11  
 DNA is the main biological target for anticancer drugs. 
Hence, the design and synthesis of DNA targeting metal-based 
anticancer agents with potential cytotoxicity have gained 
importance in recent years.12,13 Metal complexes containing 
aromatic ligands are reported to exhibit a dual-function mode of 
action, in which DNA binding occurs through both 
coordination with the metal centre, and non-covalent interaction 
such as intercalation with the DNA base pairs, along with π-π 
aromatic interactions between the double helix and the aromatic 
components of the metal complex.14-18 Moreover, some metal 
complexes with bulky ligands are shown to act as DNA groove 
binders.19-21   
 5,5-Diethylbarbituric acid (barbH), also known as 
barbitone, barbital, veronal or diemal, is a barbiturate derivative 
and is used as a sedative and hypnotic drug in the form of its 
soluble salt, sodium barbital.22 The coordination chemistry of 
barbiturates is interesting and begins with the preparation of a 
crystalline copper(II) complex of 5,5-diethylbarbiturate (barb) 
with pyridine (py), [Cu(barb)2(py)2].23 Barbituric acids are 
weak acids and readily deprotonate in aqueous solutions, 
forming corresponding barbiturate anions. The donor atoms 
such as amine N and carbonyl O atoms make the barbiturates 
interesting ligands, forming metal complexes from 
mononuclear species to coordination polymers and 
supramolecular assemblies.24 Among barbiturates, metal 
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complexes of barb have received much attention, probably due 
to its easy coordination to various metal ions.24  
 Barbiturates consist of a planar pyrimidine ring with various 
substituents on this basic skeleton and are structurally related to 
the pyrimidine nucloebases such as uracil, thymine and 
cytosine. The platinum(II) complexes of these bioligands, in 
particular those of uracil and thymine, have received 
considerable attention over the last three decades because of 
their likely relevance to the chemistry of anticancer platinum 
complexes, and the vast majority of the work was performed by 
Lippert and co-workers.25-29 On the other hand, palladium(II) 
and platinum(II) complexes of barb have not been studied 
extensively and only a few reports on the synthesis of a number 
of cis-[PtCl(barb)(L)2] complexes (L = different phosphine 
ligands)30 and the crystal structures of cis-
[PtCl(barb)(PPh3)2]·CH2Cl2,30 trans-[PtCl(barb)(PPh3)2],31 
(Et4N)6[{Pd3(Br3L)}6(μ-barb)9]32 and 
(Et3NH)4(Et4N)4[{Pd3(Br3L)}4(μ-barb)4(Hbarb)4]32 appeared in 
the literature. The barb ligand in the platinum(II) complexes is 
N-coordinated, while those in the palladium(II) complexes act 
as a bridging ligand. Although a large number of metal 
complexes of barb appeared in the literature, their biological 
evaluation received less attention and the antimicrobial activity 
of a few metal complexes of barb was reported.33-36 
 Herein we report the coordination behaviour of the barb 
ligand towards palladium(II) and platinum(II) metal ions in the 
presence of three planar aromatic ligands, 2-phenylpyridine 
(Hppy), 2,2’-bipyridine (bpy) and 2,2’-dipyridylamine (dpya). 
The title complexes are shown in Scheme 1. The interaction of 
1–6 with DNA was studied using various techniques. Further, 
the molecular docking technique was also utilized to ascertain 
the action mode of the complexes towards DNA. The 
antioxidant activity of the complexes was studied in DPPH and 
ABTS tests. Intracellular localisation of the complexes was 
determined. Cytotoxic activities were assayed against breast 
(MCF-7), colon (HT-29) and prostate (DU-145) cancer cell 
lines.   
Results and discussion 
Synthesis, characterization and stability studies 
The reaction of Hppy with PdCl2 in the presence of Na(barb) 
yields a binuclear complex of 1, while the reaction with 
K2[PtCl4] gives a mononuclear complex of 2. Complexes 3–6 
were prepared by the ligand displacement of barb with the 
chlorides in [MCl2(L)] complexes, synthesized by the methods 
reported earlier.37-40 The structure of 6 is different from those of 
the complexes. Although the same method was used to prepare 
both 5 and 6, the silver(I) ions are coordinated by barb ligands 
during the removal of chlorides by AgNO3, leading to the 
formation of  [Pt(dpya)2][Ag(barb)2]2 (6). All these complexes 
were obtained in high yields of 71-91%.  
 The formulae of the complexes were firstly deduced from 
their elemental analysis and spectroscopic data, and confirmed 
by X-ray diffraction. Our attempts to grow X-ray quality  
N N
M
N
O
N
HO
O
N
H
O
N
O
O
N
N
Pd Pd
N
O
HN
O
O
N
O
NH
O
O
Pd
N
O
N
HO
O
N N
N
H
1
3 and 4 5
N
H
O
N
O
O
6
5
4 3
6
5
4
3
6
54
3
6'
5'
4' 3'
N
Pt
N
O
N
HO
O
N
2
6
5
4 3
6*
5*
4*
3*
4*'
3*'
2*'
2
2'
1'
2
6' 5'
4'
3'2'
1'
2* 1*'
6'
5'
4'3'
6'
5'
4'
3'
2 2'
2 2'
5*'
6*'
Pt
N N
N
H
6
5
4
3
6'
5'
4'
3'
2 2'
Ag
HN
O N O
O
NN
N
H
NH
ONO
O
6
2
 
Scheme 1 A schematic representation of complexes 1–6 (M = Pd or Pt) with the 
atom numbering for NMR spectroscopy. 
crystals of 2 failed. However, based on elemental 
analysis,NMR and ESI-MS, it is assumed that it has a 
molecular structure of [Pt(barb)(ppy)(Hppy)]·3H2O, in which 
Hppy acts as a monodentate ligand, while the ppy– anion 
behaves as a bidentate cyclometalated ligand. Both 
coordination modes were observed in [Pt(ppy)(Hppy)Cl].41 The 
composition of 2 is further supported by TG/DTA analysis. The 
TG curve of 2 displays three distinct decomposition stages in 
the temperature range of 98-200, 210-370, and 375-496 °C, and 
the corresponding mass losses agree well with the removal of 
three water molecules of crystallization (found 7.5%, calc. 
7.3%), two molecules of ppy (found 41.2%, calc. 41.7%) and a 
molecule of barb (found 25.0%, calc. 24.7%) in the complex. 
 The title complexes are stable towards air and moisture, and 
are readily soluble in MeOH, EtOH and DMSO and also in the 
aqueous solutions of MeCN, MeOH and EtOH (H2O:solvent = 
1:1 v:v). The electrical conductivity measurements indicate that 
complexes 1–5 show a nonelectrolytic behaviour with ΛM 
values ranging from 11 to 21 S cm2 mol–1 in MeOH, and from 3 
to 12 S cm2 mol–1 in DMSO, while the molar conductance 
values of 6 are 172 and 74 S cm2 mol–1 in MeOH and DMSO, 
respectively, suggesting its 1:2 electrolyte nature.42 
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Table 1 Crystallographic data and structure refinement for complexes 1 and 3–6 
Complexes 1 3 4 5 6 
Empirical formula C38H38N6O6Pd2 C26H30N6O6Pd C26H30N6O6Pt C26H31N7O6Pd C52H70Ag2N14O16Pt 
M 887.54 628.96 717.65 643.98 1558.05 
T (K) 293(2) 120(2) 120(2) 120(2) 293(2) 
Crystal system triclinic monoclinic monoclinic triclinic triclinic 
Space group 𝑃𝑃1� P21/c P21/c 𝑃𝑃1� 𝑃𝑃1� 
a (Å) 12.1633(6) 11.5460(2) 11.5076(3) 11.631(7) 11.0480(4) 
b (Å) 13.0880(8) 22.1844(6) 22.3550(7) 12.252(9) 11.4890(4) 
c (Å) 14.6045(7) 13.2450(3) 13.2889(4) 12.778(15) 12.7247(5) 
α ( o) 71.039(4) 90.00 90.00 104.54(3) 72.852(3) 
β ( o) 66.529(4) 99.2996(13) 99.2282(17) 101.15(3) 86.993(3) 
γ ( o) 87.850(5) 90.00 90.00 108.709(1) 84.128(3) 
V (Å3) 2005.52(18) 3348.00(13) 3374.36(17) 1593(2) 1534.83(10) 
Z  2 4 4 2 1 
ρ (calc) (g cm−3) 1.470 1.248 1.413 1.342 1.686 
θ for data collection 1.84-26.00 3.12-27.54 3.11-27.52 1.67-26.00 1.85-26.00 
Total reflections 19968 7680 7710 6459 28112 
Independent 
reflections (Rint) 
7866  
(0.0614) 
6331  
(0.0488) 
6428  
(0.0444) 
4718  
(0.1099) 
6026                           
(0.0231)                        
Goodness of fit on F2 0.846 1.083 1.056 1.060 0.999 
R1 [I>2σ] 0.0488 0.0482 0.0321 0.0875 0.0204 
wR2 (F2) 0.1081 0.1170 0.0866 0.2626 0.0440 
 IR spectra of 1–6 display the characteristic bands of the 
ligands. For example, the ν(NH) vibration of the barb ligand 
appears at ca. 3176 cm–1, while that of dpya is observed over 
3300 cm–1. The ν(CO) vibrations of barb are observed as the 
three distinct bands in the frequency range 1630-1730 cm–1. 
The signals in the 1H NMR spectra of 1–6 are assigned 
according to the numbering in Scheme 1. The NH proton of 
barb appears as a singlet in the range of δ 10.46-10.74 ppm, 
while the signal centered at 9.65 ppm in the spectra of 5 and 6 
is attributed to the NH proton of dpya. The aromatic protons are 
observed as a multiplet between δ 8.96-6.81 ppm and 
experience deshielding compared to those of the free ligands. 
The signals observed in the range of 2.21-1.24 and 1.06-0.31 
ppm correspond to the proton resonances of the CH2 and CH3 
groups of barb, respectively. Moreover, the signals of 13C NMR 
are consistent with the number of the C atoms in the structures 
of the metal complexes. The ESI-MS spectra of 1–6 exhibit 
essential mass peaks assignable to the [M+Na]+ species 
suggesting that they retain their composition in solution and the 
presence of the peaks associated with the [M–barb]+ moieties 
also indicates the dissociation of these complexes by losing a 
barb anion under the ESI-MS ionization conditions. In the case 
of complex 6, the [Pt(dpya)2–H]+ and [Ag(barb)2+2Na]+ species 
are present in the solution. 
 Owing to their higher cytotoxicities, complexes 1, 2 and 5 
were selected for stability assay. The stability studies were 
performed in MeOH, used to prepare the stock solutions of the 
complexes, and the saline solution (0.9% NaCl), typically used 
for intravenous infusion of platinum complexes. The MeOH 
solutions were kept at room tempterature, while the saline 
solutions were incubated at 37°C. The stability of the 
complexes (1 mM) in both solutions was analyzed using 
reverse phase HPLC at 0 and 24-h intervals.43,44 The initial 
amount (t = 0 h) of the complex is considered as 100% value 
and the stability of the complex after 24 h was expressed as the 
percentage of the remaining complex compared to the initial 
amount. Stabilities of 1, 2 and 5 were estimated as 96, 95 and 
93%, respectively, in MeOH and 94, 97 and 95%, respectively, 
in the saline solution (ESI Fig. S1†). From these results, it is 
evident that the present complexes in MeOH and the saline 
solutions showed high stabilities, maintaining the integrity of 
their molecular structures after 24 h. 
Description of crystal structures 
The structures of complexes 1 and 3–6 were determined by X-
ray diffraction measurements. The summary of data collection, 
structure solution and refinement details are presented in Table 
1. The MERCURY drawings including the atom numbering 
schemes of complexes 1 and 3–6 are shown in Fig. 1. 
 The crystal structure of 1 consists of discrete binuclear 
species, in which two palladium atoms are doubly bridged by 
two barb ligands with a μ2-N/O bridging mode via the 
negatively charged N and one of the carbonyl O atoms (Fig. 1). 
The coordination of palladium(II) through the carbonyl O atom 
of barb was observed for the first time here and the N/O 
bridging behaviour of this ligand closely resembles those of the 
1-methyluracil and l-methylthymine ligands in their 
palladium(II) complexes.45,46 The pyrimidine rings of two barb  
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Fig. 1 The molecular structures of [Pd2(µ-barb)2(ppy)2] (1), [Pd(barb)2(bpy)] (3), [Pt(barb)2(bpy)] (4), [Pd(barb)2(dpya)] (5) and [Pt(dpya)2][Ag(barb)2]2·4H2O (6).  
Thermal ellipsoids are drawn at 50% probability for 1 and 40% probability for 3−6. All CH hydrogen atoms are omitted for clarity. Selected bond lengths (Å) and angles 
(°) for 1: Pd1−N1 2.022(5), Pd1−N5 2.071(5), Pd1−O1 2.179(4), Pd1−C11 1.958(6), Pd2−N2 2.024(5), Pd2−N3 2.067(5), Pd2−O4 2.162(5), Pd12−C22 1.962(7), Pd1−Pd2 
2.8909(7), C11−Pd1−N1 81.2(3), C11−Pd1−N5 94.6(3), N1−Pd1−N5 174.4(2), C11−Pd1−O1 175.0(2), N1−Pd1−O1 93.91(19), N5−Pd1−O1 90.25(18), C22−Pd2−N2 
81.3(3), C22−Pd2−N3 95.1(3), N2−Pd2−N3 176.0(2), C22−Pd2−O4 173.7(2), N2−Pd2−O4 93.4(2), N3−Pd2−O4 90.27(19); for 3: Pd1−N1 2.018(3), Pd1−N2 2.026(3), 
Pd1−N3 2.039(3), Pd1−N5 2.041(3), N1−Pd1−N2 80.67(12), N1−Pd1−N3 94.96(12), N1−Pd1−N5 175.21(11), N2−Pd1−N3 175.45(11), N2−Pd1−N5 95.97(12), 
N3−Pd1−N5 88.32(12); for 4: Pt1−N1 2.005(3), Pt1−N2 2.013(3), Pt1−N3 2.041(3), Pt1−N5 2.041(3), N1−Pt1−N2 80.38(14), N1−Pt1−N3 95.51(14), N1−Pt1−N5 
175.89(12), N2−Pt1−N3 175.70(13), N2−Pt1−N5 96.48(14), N3−Pt1−N5 87.56(14); for 5: Pd1−N1 2.040(7), Pd1−N2 2.048(6), Pd1−N4 2.051(5), Pd1−N5 2.067(5), 
N1−Pd−N2 89.1(3), N1−Pd1−N4 171.0(2), N1−Pd1−N6 93.7(2), N2−Pd1−N4 90.6(3), N2−Pd1−N6 177.1(2), N4−Pd1−N6 86.5(2); for 6: Pt1−N5 2.0143(18), Pt1−N6 
2.0155(19), Ag1−N1 2.114(2), Ag1−N3 2.109(2), N5−Pt1−N6 85.76(8), N5−Pt1−N6i 94.24(8), N1−Ag1−N3 172.91(8). Symmetry code: −x+1, −y+1, −z+1. 
ligands are perpendicular to the coordination plane in order to 
reduce steric hindrance, while the two ppy rings are oriented 
roughly parallel to each other with a dihedral angle of 10.5(2)º, 
giving rise to a weak π–π interaction of 3.767(5) Å. The 
bridging of two palladium centers results in a significantly short 
Pd−Pd distance of 2.8909(7) Å, which is similar to that of 
found in [{Pd(μ-sac)(ppy)}2] (sac = saccharinate)38 and 
[(bpy)Pd(l-MeT)2Pd(bpy)]2+ (l-MeT = l-methylthymine),46 but 
it is much shorter than those reported for the palladium 
dimers.47,48 The Pd–N(barb) distances compare well with those 
reported in the barb bridging palladium(II) complexes 
(Et4N)6[{Pd3(Br3L)}6(μ-barb)9] and 
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(Et3NH)4(Et4N)4[{Pd3(Br3L)}4(μ-barb)4(Hbarb)4], containing 
μ2-N/N bridging barb ligands.32  The Pd–C and Pd–N distances, 
and N–Pd–C angles involving the cyclometalated ppy ligands  
are well within the range reported for palladium(II) complexes 
of ppy such as [Pd(py)(sac)(ppy)], [{Pd(μ-sac)(ppy)}2],49 [Pd(μ-
Cl2)(ppy)2]50 and [Pd(ppy){P(X))Ph2}][PF6].51 The binuclear 
molecules of 1 are linked by N–H···O hydrogen bonds and π–π 
stacking interactions of 3.5846(2) Å, involving the ppy rings. 
 Complexes 3 and 4 are isostructural with a molecular 
formula of [M(barb)2(bpy)] (Fig. 1). The large distortions in the 
square-planar geometry of both complexes are originated from 
the bite angle of bpy [80.67(12)° for 3 and 80.38(14)° for 4]. In 
addition, due to the presence of two alkyl groups, the barb 
ligands tend to be oriented to each other with dihedral angles of 
73.2(2) and 72.9(2)° for 3 and 4, respectively. Similar repulsive 
forces were observed between the methyl groups of two 
mesitylene (mes’) ligands in [(np)Pt(mes’)2]Cl2.52 The M–
N(bpy) bond distances are in the expected range for 
palladium(II) and platinum(II) complexes of this type.46, 53-61 
Both M–N(barb) bond distances are typical of those found in 
palladium(II) and platinum(II) complexes containing the 
monodentate barb ligand.30-32 The molecules of 3 and 4  are 
linked by the N–H···O hydrogen bonds along the c axis to form 
hydrogen-bonded chains. Then, these chains are further 
connected via π–π interactions.  
 Complex 5 consists of individual molecules of 
[Pd(barb)2(dpya)], in which the dpya ligand coordinates to the 
palladium(II) ion via two pyridyl N atoms, while both barb 
ligands are N-bonded (Fig. 1). The dpya ligand is not planar 
and adopts a boat conformation and the dihedral angle between 
two py rings is 21.1(3)°. Again, the pyrimidine rings of the barb 
ligands are oriented with a dihedral angle of 73.8(2)°. The Pd–
N(barb) distances are somewhat longer than those found in 3, 
while the Pd–N(dpya) bond distances are close agreement with 
those found in palladium(II) complexes of the dpya 
ligand.39,62,63 In the crystal, the molecules are triply bridged by 
the N–H···O hydrogen bonds, leading to layers propagating in 
the (000) plane.  
 As shown in Fig. 1, complex 6 is composed of a 
[Pt(dpya)2]2+ cation, two [Ag(barb)2]− anions and four water 
molecules of crystallization. In the cation, the platinum(II) ion 
is located on the inversion centre and coordinated by two 
bidentate dpya ligands. The Pt–N(dpya) bond distances are 
similar to those reported for the platinum(II) complexes of 
dpya.39,40,65-67 In the complex anion, the silver(I) ion is 
coordinated lineraly by two barb ligands. The Ag–N(barb) bond 
distances compare well with the corresponding bonds found in 
the silver(I) complexes containing linearly coordinated barb 
ligands.33,34,68,69 In the crystal, the [Ag(barb)2]− anions are 
linked by N–H···O hydrogen bonds into a chain and  the 
[Pt(dpya)2]2+ cations are further connected to these chains, 
through symmetrically related water molecules, by OW–H···O 
hydrogen bonding interactions to form a three-dimensional 
supramolecular network.  
 
Interaction with DNA 
 Electronic absorption titration. The UV-Vis spectra of 
complexes 1−6 in the absence and presence of FS-DNA 
exhibited a hyperchromic effect around ca. 245 nm (Table 2, 
Fig. 2, ESI Fig. S2†). The spectra of 1, 2, 5 and 6 displayed a 4 
nm red-shift, while no shift was observed in those of 3 and 4. In 
order to compare the DNA binding affinities, the intrinsic 
binding constant Kb was calculated using the equation:70  
               [DNA]/(εa–εf) = [DNA]/(εb–εf) + 1/Kb(εb–εf)                   (1) 
where [DNA] is the concentration of DNA in base pairs, εa, εf 
and εb correspond to Aobs/[M], the extinction coefficient of the 
free metal complex and the extinction coefficient of the 
complex in the fully bound form, respectively. The ratio of 
slope to intercept in the plot of [DNA]/(εa–εf) versus [DNA] 
gives the value of Kb. The Kb values in Table 2 range from 4.5 x 
104 to 2.0 x 105 M−1, suggesting a significant association of 
these complexes with FS-DNA. Complexes 1 and 2 showed 
higher Kb values, which are the same as that observed for the 
hyperchromism. However, their binding constants are similar to 
those of some platinum(II) complexes of bpy and terpy,18,71 but 
they are lower than that reported for the classical intercalator, 
ethidium bromide (EB) (Kb = 1.4 x 106 M−1)72 and the 
platinum(II) complexes with bpy and derivatives.73  
 
Fig. 2 Electronic absorption spectra of complexes 1 (25 μM) upon the titration of 
FS-DNA (0–50 μM) in Tris-HCl buffer. The arrow shows the increases in 
absorbance with respect to an increase in the FS-DNA concentration. The inset 
shows the linear fit of [DNA]/(εa − εf ) vs. [DNA] and the binding constant (Kb) was 
calculated using equation (1). 
 Ethidium bromide exchange. An appreciable decrease in 
emission intensity of EB bound FS-DNA was observed upon 
incremental addition of 1−6 (Fig. 3 and ESI Fig. S3†) and is 
indicative of an intercalative or minor groove binding.74–78 The 
quenching ability of the complexes is evaluated by the Stern-
Volmer quenching constant (KSV):79,80 
F0/F = 1 + KSV[Q] = 1 + kqτ0[Q]                        (2) 
where F0 and F are the fluorescence intensities in the absence  
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and presence of the complexes, respectively. [Q], kq and τ0 are 
the total concentration of the quencher (1–6), the quenching 
rate constant and the average lifetime of EB-DNA in the 
absence of the quencher (τ0 = 10–8 s)81, respectively. On the 
other hand, the apparent binding constant (Kapp) is determined 
from the equation (3).74 
KEB[EB] = Kapp[Q]                                         (3) 
in which [Q] is the concentration of the quencher causing a 
50% reduction in the fluorescence intensity of EB-bound DNA, 
KEB = 1.0 x 107 M−1 and [EB] = 5.0 μM.  
 The KSV and Kapp values in Table 2 suggest that 6 has a 
negligible effect on the fluorescence intensity of the EB-FS-
DNA solutions, while the others bind significantly to DNA, 
suggesting intercalative or minor groove mode of binding. 
Among all complexes, 1 and 5 exhibit stronger binding 
propensity. 
 Since dynamic and static quenching processes are both 
temperature dependent The KSV values estimated from the 
measurements performed at 293, 301 and 310 K were gradually 
decreased with the increasing of the temperature and clearly 
indicate a static quenching path.81 
 Hoechst 33258 displacement. The competitive DNA 
binding measurements with Hoechst 33258 showed that the 
addition of complexes 1 and 3 resulted in a significant decrease 
in the fluorescence intensity of the Hoechst-DNA solutions 
(Fig. 3 and ESI Fig. S4†). The quenching constant of 1 
(63.6±1.6 x 104 M−1) is approximately 7-fold higher than that of 
3 (8.7±0.2 x 104 M−1). However, the rest of the complexes have 
practically no influence on the intensity of the Hoechst-DNA 
system. Thus, complexes 1 and 3 displace the minor-groove 
fluorogen Hoechst 33258 with greater specificity than 
intercalated EtBr and may be considered as DNA minor groove 
binders.  
 Viscosity studies. The relative viscosity of the FS-DNA 
solutions increases steadily, to a small extent, with increasing 
concentrations of 1–6. The corresponding data were presented 
in ESI Fig. S5† as (η/η0)1/3 versus the ratio of the concentration 
(r) of the complex-FS-DNA solutions, where η is the viscosity 
of DNA in the presence of complex, and η0 is the viscosity of 
DNA alone in the buffer solution.82 The higher viscosity values 
were observed for 2 and 5. The results of the viscosity 
measurements indicate that the complexes bind to FS- DNA via 
threading intercalation, being partially intercalated to DNA as 
well as binding within the grooves of DNA.83,84  
 DNA melting studies. The dissociation of the double 
strands into single strands occurs as the temperature of DNA 
solutions increases and the temperature at which half of the 
total base pairs is unpaired is defined as the DNA melting  
Table 2 Binding (Kb and Kapp) and quenching constants (KSV) for the 
interaction of 1–6 with FS-DNA 
 
Complexes 
UV titration EB exchange 
Kb (M−1) 
x 10−4 
∆ε (%) KSV (M−1) 
x 10−4 
Kapp (M−1) 
x 10−6 
1 20.0 ± 2.4 35.6 4.7 ± 0.1 4.0 
2 10.0 ± 0.8 25.4 3.2 ± 0.2 1.5 
3 5.5 ± 0.1 10.4 2.4 ± 0.2 1.0 
4 6.0 ± 0.1   19.5 1.4 ± 0.1 1.0 
5 7.0 ± 0.4   31.2 4.9 ± 0.1 2.0 
6 4.5 ± 0.1   23.8 0.5 ± 0.1 − 
 
(a) 
 
(b) 
Fig. 3 Emission spectra of EB-bound (a) and Hoechst 33258-bound (b) DNA 
solutions in the absence and presence of increasing concentrations of complexes 
1 (12.5–100 μM for a and 2.5–25 μM for b in Tris-HCl buffer. [EB] = [Hoechst 
33258] = 5.0 μM, [DNA] 50.0 μM. r = [complex]/[DNA]. The arrows show the 
changes in intensity upon increasing amounts of the complexes. Insets: Stern-
Volmer plot of the fluorescence data.  
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temperature (TM).85,86 Thermal melting on FS-DNA(ESI Fig. 
S6†) revealed that complexes 1, 2, 5 and 6 extensively 
stabilized the thermal denaturation (ΔTM = 6, 15, 11, 3 ºC, 
respectively), while the other complexes yielded either no or 
negligible effects under our tested conditions. In general, a high 
∆TM value corresponds to an intercalative mode of binding of a 
metal complex to DNA, while a low value indicates a non-
intercalative binding mode.87-89 
DNA Cleavage 
 Electrophoretic mobility. The chemical nuclease activity 
of complexes 1−6 towards the supercoiled plasmid pUC19 
DNA was studied by agarose gel electrophoresis in the absence 
of any external effect such as UV light, reducing and oxidizing 
agents. The nuclease efficiency of the complexes was assessed 
by their ability to convert the closed circular supercoiled from 
of the DNA (form I) to the open circular relaxed form (form II) 
or the linear form (form III). All complexes were initially 
interacted with the plasmid DNA at the various 
[complex]/[DNA] ratios (r) of 0.5, 1.0, 2.0 and 5.0 in a 
relatively short incubation time (30 min) at 37 °C. It was shown 
that the plasmid DNA is not cleaved in the presence of 
complexes 5 and 6, being very similar to the control, while the 
mobility of the form I band decreases with increasing amounts 
of 3 and 4, indicating conformational changes (unwinding) in 
the plasmid DNA due to the non-covalent binding of these 
complexes (Fig. 4). In contrast, the lanes for 1 and 2 contained 
no bands corresponding to form I or any cleaved form II or 
form III; instead, a smearing of DNA occured giving a clean gel 
image without any DNA residue in the gel even at r = 0.2. 
When the two complexes were restudied at much lower r values 
between 0.05-0.2, the form I band became discernible as a faint 
band with smearing at r = 0.05 for 1 and 0.075 for 2 compared 
to control (Fig. 4). Again, no forms of II and III were detected. 
The DNA smears reveal that EB used to stain DNA in the gel is 
completely expelled out of the plasmid DNA due to strong 
intercalation or groove binding of these complexes, leading to 
quenching of the EB emission (see competitive binding 
studies). Similar behavior of the plasmid DNA in the gels 
stained with EB was reported previously for ruthenium(II) 
complexes bearing diimine ligands such as dpya90 and phen.91  
 Inhibition of restriction enzymes. To investigate binding 
preference of complexes 1−6, a restriction enzyme inhibition 
assay was used. Restriction enzyme inhibition by metal 
complexes is due to the fact that when a metal complex binds at 
the unique binding site of a restriction enzyme on DNA, it tends 
to inhibit the endonuclease activity of the enzyme by blocking 
its recognition site.92-94 Consequently, a metal complex that 
inhibits a restriction enzyme is said to bind selectively.  
 In this study, two representative restriction enzymes, which 
differ in their target sequence, namely HindIII (recognition site 
AAT↓ATT) and BamHI (recognition site G↓GATCC), were 
chosen. Both enzymes have single restriction site in pUC19 
plasmid DNA and were tested to observe inhibition of their 
endonuclease activity by presence of the complexes (Fig. 5). 
The formation of the linear form of pUC19 (form III) is clearly  
 
Fig. 4 Agarose gel electrophoresis images of pUC19 plasmid DNA incubated for 
30 min at 37 °C with increasing concentrations of complexes 1–6. Lane 0: pure 
plasmid DNA; lanes 1-4: DNA + complexes with r = 0.05, 0.075, 0.1 and 0.2, 
respectively, for complexes 1 and 2 and r = 0.5, 1.0, 2.0 and 5 for complexes 3–6. 
Each sample contains 200 ng of plasmid DNA.  
   
 
Fig. 5 Restriction endonuclease activity of complexes 1–6 towards pUC19 
plasmid DNA. Agarose gel electrophoresis images showing formation of 
restriction digestion products of HindIII and BamHI enzymes on pUC19 after 
incubation with complexes 1–6. Lane 0: pure plasmid DNA; lane 1: enzyme + 
DNA; lanes 2-8: enzyme + DNA + complexes 1–6, respectively. r = 0.05 for 
complexes 1 and 2; r = 1.0 for complexes 3–6. 
visible only for complex 3 in both cases. The activity 
introduced in the plasmid by HindIII restriction endonuclease 
was found to be notable for complexes 1−6, indicating their 
preference to the A/T binding. Moreover, complexes 1, 3 and 5 
have a tendency to bind with both G/C and A/T rich sequences.    
Molecular docking  
Molecular docking is a well-established computational 
technique for predicting the interaction between the molecules 
and DNA, and to find the binding and best orientation of the 
molecule, which would form a new complex with overall 
minimum energy. In this context, the Protein Data Bank was 
searched and two structures of B-DNA were selected: a 
dodecamer d(CGCGATATCGCG)2 (1DNE) for groove binding 
and an octamer d(GAAGCTTC)2 (1DSC) for intercalation.95 
Then, complexes 1−6 were docked into DNA to study the 
proper binding site along with preferred orientation of the 
complexes inside these DNA duplexes. The lowest-energy  
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2 
Fig. 6 Computational docking models (using the Autodock/Vina software) 
illustrating the interactions between DNA and complexes 1 and 2.                       
conformations show that 1 and 3 bind to the minor groove near 
the domain of the G base (Fig. 6 and ESI Fig. S7†), while 
complexes 2, 4−6 interacts with DNA with a partial 
intercalation together with hydrogen bonding interactions with 
the A rich regions in the grooves.  
 There are weak π–π stacking interactions between the 
aromatic rings in complexes 2, 4, 5 and DNA. Furthermore, all 
complexes favour the formation of hydrogen bonding mainly 
through the barb ligands, which act as hydrogen bond donor 
and acceptor due to the presence of the NH and carbonyl 
groups (Table S1). The [Pt(dpya)2]2+ cation in 6 is not involved 
in hydrogen bonding and interacts electrostatically with DNA, 
while the [Ag(barb)2]− anion forms two hydrogen bonds with 
the A and C bases (ESI Fig. S7†). Overall, these interactions 
contribute significantly to the stabilization of each complex 
within the DNA duplex.  
 The DNA binding affinity of the complexes may be 
predicted from the binding free energy. The calculated binding 
free energies for 1−6 are in the range of 27.61-32.22 kJ mol−1 
(Table S1) and follow the same order obtained for the binding 
constants of the complexes. Finally, the modes of binding of the 
complexes with DNA obtained from molecular docking studies 
correspond well with the experimental findings. 
Table 3 Radical scavenging activities of complexes 1–6  
 
Compounds 
IC50 (µM) ± esd 
DPPH• ABTS•+ 
1 52.3 ± 1.7 51.2 ± 3.4 
2 39.7 ± 1.3 28.9 ± 2.3 
3 99.7 ± 3.2 92.8 ± 1.4 
4 136.2 ± 3.9 113.6 ± 2.7 
5 117.8 ± 3.3 108.2 ± 3.1 
6 121.4 ± 2.6 111.3 ± 4.2 
Na(barb) 34.1 ± 1.9 30.2 ± 2.4 
BHT 15.9 ± 1.2 11.4 ± 1.1 
Ascorbic acid 11.3 ± 1.6 4.1 ± 0.9 
Antioxidant properties 
The presence of hydrogen donating ligands allows the 
suggestion that these complexes may display antioxidant 
properties. The antioxidant potentials of complexes 1−6 were 
tested by two models, namely 2,2-diphenyl-2-picryl-hydrazyl 
(DPPH) and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic 
acid) (ABTS), and compared with well-known standards such 
as the natural antioxidant ascorbic acid and a synthetic 
antioxidant butylated hydroxytoluene (BHT). The DPPH 
radicals are stable in solution, being a useful reagent for the 
investigation of the radical scavenging activity of phenols, 
catecholes, thiols etc..96 The radical activity of a compound can 
be monitored spectrophotometrically by measuring the decrease 
in the absorbance of DPPH at 517 nm as well as a colour 
change from violet to yellow. The ABTS test is usually used to 
evaluate the total antioxidant capacity of many compounds,97 
because the ABTS radical can react not only with the hydrogen 
donating compounds such as phenols, but also with any 
compound giving a hydrogen atom or an electron. The 
absorption of the ABTS•+ radical centred at ca. 740 nm (giving 
a bluish-green colour) diminishes rapidly in the presence of an 
antioxidant, yielding the solution decolourization.  
 The scavenging effects of the complexes and the standards 
on DPPH and ABTS radicals were expressed as IC50 values, 
which correspond to the 50% inhibitory concentration (Table 
3). The antioxidant activity of the complexes increased with 
increase in the concentration of the complexes. In general, the 
DPPH and ABTS radical scavenging activity of the complexes 
was low in comparison to that of the standard compounds. 
Moreover, the complexes were more effective in inhibition of 
the ABTS radical than the DPPH radical. Complexes 1 and 2 
present a moderate reducing ability of both radicals. The IC50 
values demonstrate that in each case, complex 2 exhibits greater 
antioxidant activity than the other complexes. The barb ligand 
contains an acidic NH group and the antioxidant activityof 
Na(barb) is most likely due to the donation facility of the NH 
hydrogen to the DPPH and ABTS free radicals. The lower 
radical scavenging activity of the complexes compared to 
Na(barb) under the same experimental conditions suggests that 
the H donation ability of the barb ligand significantly decreases 
upon coordination. The observed antioxidant activity of the 
complexes may be due to reduction in the radical character of 
DPPH  and ABTS by transfer of a hydrogen atom from the barb 
ligands, rather than an electron donation.   
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Table 4 In vitro cytotoxic activity of complexes 1–6 after 48 h incubation 
 
Complexes 
IC50 (µM) ± esd 
HT-29 MCF-7 DU-145 PNT1A 
1 37.3 ± 0.9 50.4 ± 5.3 26.6 ± 1.1 81.2 ± 1.1 
2 62.9 ± 1.7 78.4 ± 1.6 39.4 ± 1.8 52.7 ± 0.9 
3 164.5 ± 8.8 98.7 ± 5.4 193.6 ± 5.0 124.5 ± 1.0 
4 >300 224.9 ± 16.4 >300 142.6 ± 1.5 
5 28.7 ± 1.8 41.2  ± 2.5 34.1 ± 3.1 64.1 ± 2.9 
6 >300 230.6  ± 8.1 >300 123.1 ± 7.9 
Cisplatin 42.0 ± 5.2 30.7 ± 1.3 4.5 ± 0.4 12.3 ± 0.9 
Carboplatin >300 >300 85.8 ± 10.2 108.3 ± 12.4 
Oxaliplatin 44.4 ± 2.4 19.6 ± 1.8 4.3 ± 1.1 17.9 ± 0.7 
Cellular uptake 
Cellular uptake experiments are essential for the evaluation of 
permeability and mechanisms of transport of metal compounds 
on the cellular level. Human prostate cancer cells (DU-145) 
were incubated with the selected complexes (1, 2 and 5) (50 
μM) at 37 °C for 1 h and the Pd and Pt contents in the different 
subcellular fractions (membrane, cytoskeleton, cytosol and 
nucleus) were determined by ICP-MS. Fig. 7 shows the 
distribution of the complexes between these fractions. The total 
cellular uptake of 2 (2.86 ng Pt/106 cells) is comparable to 
cisplatin (2.70 ng Pt/106 cells) in the same conditions, but 
higher than those of 1 (2.43 ng Pd/106 cells) and 5 (1.37 ng 
Pd/106 cells). In addition, it should also be noted that less than 
2.7% of the applied complexes was taken up by the cells during 
their incubations. Complex 2 is almost uniformly distributed 
between the four cellular fractions and shows the highest 
nuclear uptake compared to the other complexes. However, 1 is 
accumulated mostly in the cytosol and membrane, while 5 is 
deposited in membrane and cytoskeleton fractions. The cellular 
uptake studies indicate that the complexes efficiently enter into 
DU-145 cells. The Pd and Pt levels of each complex differ in 
the subcellular fractions and the cellular uptake does not 
strongly correlate with the cytotoxicity of the present 
complexes. Similar observations were reported for platinum(II) 
complexes, when a constant dose is applied.44,98  
In vitro cytotoxic activity 
The encouraging results observed in DNA binding and DNA 
cleavage studies have directed us to investigate the cell growth 
inhibition of the title complexes. In vitro cytotoxic activities of 
complexes 1−6 against human carcinoma cell lines namely 
MCF-7 (breast), HT-29 (colon), DU-145 (prostate) and PNT-
1A (human prostatic epithelial cell) were assessed by MTT 
assay. The concentrations of the complexes ranged from 3.125 
μM to 300 μM. The cytotoxic activity of the complexes was 
shown to be dose-dependent. The IC50 values (50% inhibition 
of cell growth) of the complexes together with those of 
cisplatin, carboplatin and oxaliplatin after a 48 h treatment are 
given in Table 4. These values demonstrate that in general 
complexes 1, 2 and 5 showed certain inhibitory effect on all 
cancer cell lines, while complexes 3, 4 and 6 were found 
practically ineffective. Complexes 1, 2 and 5 exhibited higher 
in vitro cytotoxicity than carboplatin in all cases, and also the 
activities of 1 and 5 against the HT-29 cells are greater than the 
three clinically used metallodrugs. In addition, these complexes 
had much lower toxicity on the prostatic epithelial cells (normal 
cells), confirming that they act selectively for the HT-29 cells. 
Further studies are warranted to assess their biological 
properties in vivo and elucidate their actual mechanisms. On 
the other hand, there are differences in the cytotoxic activity of 
the present metal complexes. For example, 5 is the most 
cytotoxic on both HT-29 and MCF-7 cells, while 1 is most 
potent against DU-145 cells. Morever, 2 exhibits an activity 
between them. Although the complexes interact with DNA 
strongly, they display only moderate activities against the cells. 
These findings indicate that the cytotoxicity of the complexes is 
not correlated with their DNA binding propensities.  
 
(a) 
 
(b) 
Fig. 7 Subcellular distribution of 1, 2, and 5 in DU-145 cells after 1 h of incubation 
at 37 °C with 50 μM concentration. (a) % of total uptake in the different 
fractions and (b) % of intracellular uptake of total amount applied. 
This journal is © The Royal Society of Chemistry 2013 J. Name., 2013, 00, 1-3 | 9  
ARTICLE Journal Name 
Conclusions 
Six new 5,5-diethylbarbiturato complexes of palladium(II) and 
platinum(II) with  2-phenylpyridine, 2,2’-bipyridine and 2,2’-
dipyridylamine ligands were synthesized and characterized. 
The molecular structures of the complexes 1 and 3−6 were 
determined by single crystal X-ray diffraction, while that of 2 
was deduced from elemental analysis, NMR and ESI-MS 
measurements. Complex 1 has a binuclear structure, while 
complexes 2–6 consist of mononuclear species. The UV-Vis, 
fluorescence spectroscopy, thermal denaturation and viscosity 
measurements revealed that the complexes bind strongly to FS-
DNA. The binding constants of the complexes with DNA 
calculated for electronic absorption and fluorimetric 
competetive titrations showed that complexes 1, 2 and 5 has 
higher binding affinity to DNA than the rest of the complexes. 
In addition, only 1 and 2 alters the DNA superhelicity upon 
binding with supercoiled pUC19 DNA, which is consistent with 
their higher DNA binding affinities. Based on the experimental 
data as well as DNA docking studies, the mode of binding was 
suggested as minor groove recognition for 1 and 3, threading 
intercalation for 2 4 and 5, and a combination of electrostatic 
and groove binding for 6. The cellular uptake studies suggest 
that in addition to DNA, these complexes might also interact 
with other cellular components. The antioxidant studies 
indicated that complexes 1 and 2 exhibited moderate activities 
compared to the reference antioxidants butylated 
hydroxytoluene and ascorbic acid. In addition, in vitro 
cytotoxic activities of the complexes against breast (MCF-7), 
colon (HT-29) and prostate (DU-145) cancer cell lines were 
assayed. Complexes 1 and 5 showed considerable cytotoxic 
activity specifically against HT-29 cells compared to clinically 
used metallodrugs such as cisplatin, carboplatin and oxaliplatin. 
However, the strong DNA binding ability of the complexes 
does not result in high cytotoxic activity against the cancer 
cells.  
Experimental 
Materials and measurements  
All chemicals used in the experiments were purchased 
commercially and used without further purification. The 
starting complexes, [MCl2(L)] (M = PdII or PtII; L = bpy37,38 or 
dpya39,40), were prepared as described in the literature. 
Tris(hydroxymethyl)aminomethane (Tris-HCl), ethidium 
bromide (EB), Hoechst 33258, 2,2-diphenyl-1-picrylhydrazyl 
(DPPH), 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
(ABTS), L-ascorbic acid, butylated hydroxytoluene (BHT),  
plasmid DNA pUC19 and fish sperm (FS)-DNA, were obtained 
from Sigma, and loading buffer (10×) from was obtained from 
Dr. Zeydanli. The FractionPREP cell fractionation kit was 
purchased from Biovision. Doubly distilled water was used as 
the solvent throughout the experiments. The stock solution of 
FS-DNA was prepared in Tris-HCl buffer (20 mM Tris-HCl/20 
mM NaCl buffer at pH 7.0). All stock solutions were stored at 5 
°C and used within 3 days. The ratio of the UV absorbance at 
260 and 280 nm (A260/A280) was checked to be ca. 1.86, 
indicating that the DNA is sufficiently free from protein 
contamination.99 The DNA concentration per nucleotide 
phosphate [NP] was determined by the UV absorbance at 260 
nm after 1:20 dilutions using the known ε value of 6600 
M−1cm−1.100 
 Elemental analyses for C, H, and N were performed using a 
Costech elemental analyser. UV-Vis spectra were measured on 
a Perkin Elmer Lambda 35 spectrophotometer. IR spectra were 
recorded on a Perkin Elmer Spectrum Two FT-IR 
spectrophotometer. 1H NMR and 13C NMR spectra were 
recorded on a Varian Mercuryplus spectrometer at 400 and 100 
MHz, respectively, in DMSO-d6 using Me4Si as internal 
reference at room temperature. Fluorescence spectra were 
recorded at room temperature with a Varian Cary Eclipse 
spectrophotometer equipped with a Xe pulse lamp of 75 kW. 
For all fluorescence measurements, the slits were maintained at 
5 nm. The ESI mass spectra were recorded using a Bruker 
Daltonics Microtof II-ESI-TOF mass spectrometer. The 
electrical conductivity measurements of the complexes in 
MeOH and DMSO were carried out with Inolab Cond 730 
conductimeter at room temperature and reported as ΛM (S cm2 
mol–1). Melting points are measured using a BUCHI 560 
instrument and a capillary apparatus. The agarose gel 
electrophoresis was performed using UVITEC imaging and gel 
documentation systems. 
Synthesis of palladium(II) and platinum(II) complexes 
 Synthesis of [Pd2(µ-barb-κN,O)2(ppy-κN,C)2] (1). 71 µL 
(0.5 mmol) of 2-phenylpyridine (Hppy) was added to the 
solution of PdCl2 (0.09 g, 0.5 mmol) dissolved in 25 mL of 
MeCN and this solution was refluxed at 60 °C for 3 h. Then, 10 
mL aqueous solution of Na(barb) (0.154 g, 0.75 mmol) was 
added to this solution and stirred at 60 °C for 1 h. The yellow 
precipitate was filtered off and recrystallized from a mixture of 
MeCN, DMSO and isopropyl alcohol (1:1:1) (yield: 0.536 g, 
76%; mp (decomp.) 330–334 °C). Anal. calc. for 
C38H38N6O6Pd2 (%): C, 51.42; H, 4.32; N, 9.47. Found: C, 
51.21; H, 4.65; N, 9.69. IR (KBr, ν/cm–1) 3189m (NH-barb), 
3067w (arom. CH), 2968w (aliph. CH), 2934w (aliph. CH), 
1727m (CO), 1703s (CO), 1678vs (CO), 1606vs (CN), 1577s 
(CC), 1488m, 1403s, 1313vs, 1256vs, 1167w, 1019m, 950w, 
828m, 737vs, 720vs, 548vs, 469m.  1H NMR (400 MHz; 
DMSO-d6; Me4Si): δ (ppm) 10.74 (s, 2H, NH-barb),  9.25 
(broad s, 2H, H6-ppy), 8.46 (broad s, 2H, H4-ppy), 8.04 (broad 
s, 6H, H3, H5, H6’-ppy), 7.74-7.57 (t, 3J(HH)  = 6.8 Hz, 2H, H5’-
ppy), 7.40 (broad s, 4H, H6’, H4’-ppy), 7.14-6.95 (t, 3J(HH)  = 
7.7 Hz, 2H, H3’-ppy), 1.82-1.76 (q, 8H, 3J(HH) = 7.6 Hz, CH2-
barb), 0.73-0.69 (t, 12H, 3J(HH)  = 7.6 Hz, CH3-barb). 13C 
NMR (100 MHz, DMSO-d6; Me4Si): δ 173.5, 165.8, 163.7 CO 
barb, 151.0 C2-ppy, 148.3 C6-ppy, 141.3 C1’-ppy, 136.7 C4-
ppy, 132.9 C4’-ppy, 130.0 C5’-ppy, 129.0 C3’-ppy, 126.6 C2’-
ppy, 125.1 C3-ppy, 120.0 C5-ppy 56.9 CEt2-barb, 31.6 CH2-
barb, 9.6 CH3-barb. UV λmax (MeOH)/nm 304, 314 and 325 
(ε/dm3 mol–1 cm–1 15200, 14400 and 10000). Molar 
conductivity, ΛM (1×10−3 M, MeOH) 15 S cm2 mol−1 
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(nonelectrolyte) and ΛM (1×10−3 M, DMSO) 6 S cm2 mol−1 
(nonelectrolyte). ESI-MS (m/z, MeOH): 910.2 [M+Na]+ (calc.: 
910.6), 852.8 [Pd2(ppy)2(μ-ppy)2+Na]+ (calc.: 852.6).  
 Synthesis of [Pt(barb)(Hppy-κN)(ppy-κN,C)]·3H2O (2). 
71 µL (0.5 mmol) of Hppy was added to the solution of 
K2[PtCl4] (0.21 g, 0.5 mmol) dissolved in 10 mL of water and 
this solution was refluxed at 60 °C for 1 h. Then, 10 mL 
aqueous solution of Na(barb) (0.154 g, 0.75 mmol) was added 
to this solution and stirred at 60 °C for 1 h. The yellow 
precipitate was filtered off and air-dried (yield: 0.526 g, 71%, 
mp 180–184 °C). Anal. calc. for C30H34N4O6Pt (%): C, 48.58; 
H, 4.62; N, 7.55. Found: C, 48.43; H, 4.65; N, 7.69. IR (KBr, 
ν/cm–1) 3498b (OH), 3176w (NH-barb), 3066m (arom. CH), 
2969m (aliph. CH), 2938w (aliph. CH), 1714m (CO), 1681s 
(CO), 1607s (CN), 1559w, 1473s (CC), 1424m, 1362m, 1316s, 
1244m, 1161m, 1072w, 1014w, 998w, 760s, 741vs, 696vs, 
553m. 1H NMR (400 MHz, DMSO-d6; Me4Si): δ (ppm)  10.46 
(s, 1H, NH-barb), 8.56 (s, 2H, H6, H6*-ppy),   8.05-7.91 (d, 
3J(HH)  = 8.4 Hz,  3H, H2’*, H6’, H4-ppy),  7.85-7.76 (t, 3J(HH)  
= 7.6 Hz, 2H, H3*, H3-ppy),  7.73-7.68 (td, 3J(HH)  = 7.2 Hz, 
3H, H4*, H5*, H5-ppy),  7.49-7.38 (dd, 3J(HH)  = 7.2 Hz, 2H, 
H3’, H4’-ppy), 7.25-7.22 (d, 3J(HH)  = 6.8 Hz, 2H, H5’*,  H6’*-
ppy), 6.84-6.80 (t, 3J(HH)  = 5.6 Hz, 3H, H5’, H4’*, H3’*-ppy), 
1.72-1.69 (q, 4H, 3J(HH) = 7.2 Hz, CH2-barb), 0.65-0.61 (t, 6H, 
3J(HH)  = 7.2 Hz, CH3-barb). 13C NMR (100 MHz, DMSO-d6; 
Me4Si): δ 173.5, 162.7 CO barb, 159.6 C2*-ppy, 154.3 C2-ppy, 
153.5 C6-ppy, 151.4 C6*-ppy, 150.2 C1’*-ppy, 149.8 C2’*-
ppy, 139.2 C1’-ppy, 138.7 C4*-ppy, 137.1 C4-ppy, 132.5 C4’*-
ppy, 131.2 C3’-ppy, 129.8 C2’-ppy, 129.2 C3’-ppy, 127.6 C4’-
ppy, 126.9 C5-ppy, 126.5 C6’*-ppy, 124.6 C5’*-ppy, 123.5 
C5*-ppy, 121.3 C3*-ppy, 56.9 CEt2-barb, 31.7 CH2-barb, 9.6  
CH3-barb. UV λmax (MeOH)/nm 277, 307 and 328 (ε/dm3 mol–1 
cm–1 20800, 8400 and 6000). Molar conductivity, ΛM (1×10−3 
M, MeOH) 11 S cm2 mol−1 (nonelectrolyte) and ΛM (1×10−3 M, 
DMSO) 6 S cm2 mol−1 (nonelectrolyte). ESI-MS (m/z, MeOH): 
710.2, [M+Na]+ (calc.: 710.7), 504.5 [Pt(ppy-κN,C)2+H]+ 
(calc.: 504.1). 
 Synthesis of [Pd(barb-κN)2(bpy-κN,N’)] (3). The solid 
AgNO3 (1 mmol, 0.17 g) was added to a suspension of 
[PdCl2(bpy)] (0.5 mmol) in water (200 mL) and then, this 
suspension was refluxed for 6 h. After cooling to room 
temperature, the precipitate of AgCl was removed by filtering 
through Celite paste to obtain a clear yellow solution. The 
filtrate was concentrated to ca. 25 mL and followed by the 
addition of Na(barb) (1 mmol, 0.21 g) and stirred at 60 °C for 1 
h. As soon as the addition of Na(barb), a yellow precipitate was 
formed. The final suspension was cooled to the room 
temperature and filtered off to separate the yellow solid. The 
powders were recrystallized from to yield their DMSO solvate 
crystals of [Pd(barb)2(bpy)] (yield: 0.773 g, 86%, mp (decomp.) 
368–372 °C). Anal. calc. for C26H34N6O8Pd (%): C, 46.96; H, 
5.15; N, 12.64. Found: C, 47.20; H, 4.84; N, 12.44. IR (KBr, 
ν/cm–1) 3175w (NH-barb), 3084w (arom. CH), 3044w (arom. 
CH), 2938w (aliph. CH), 2854w (aliph. CH), 1716m (CO), 
1687s (CO), 1633vs (CO), 1601m (CN), 1499w, 1449m (CC), 
1366s, 1323vs, 1247m, 1160w, 1039w, 949w, 771m, 545w.  1H 
NMR (400 MHz, DMSO-d6; Me4Si): δ (ppm) 10.76 (s, 2H, 
NH-barb),  8.96-8.46 (d, 2H, 3J(HH) = 7.2 Hz, H6, H6’-bpy), 
8.31 (s, 2H, H3, H3’-bpy), 7.92 (s, 2H, H4, H4’-bpy), 7.69 (s, 2H, 
H5, H5’-bpy), 2.21-1.44 (m, 8H, 3J(HH) = 7.6 Hz, CH2-barb), 
1.06-0.31 (d, 12H, 3J(HH) = 7.6 Hz, CH3-barb). 13C NMR (100 
MHz, DMSO-d6; Me4Si): δ 178.5, 175.2, 156.7 CO barb, 155.5 
C2-bpy, 151.2 C6-bpy, 141.8 C4-bpy, 127.7 C3-bpy, 124.4 C5-
bpy, 56.4 CEt2-barb, 32.1 CH2-barb, 10.2 CH3-barb. UV λmax 
(MeOH)/nm 239, 308 and 315 (ε/dm3 mol–1 cm–1 30000, 15600 
and 14400). Molar conductivity, ΛM (1×10−3 M, MeOH) 12 S 
cm2 mol−1 (nonelectrolyte) and ΛM (1×10−3 M, DMSO) 7 S cm2 
mol−1 (nonelectrolyte). ESI-MS (m/z, MeOH): 651.1, [M+Na]+ 
(calc.: 651.9), 445.1 [M–barb]+ (calc.: 445.7). 
 Synthesis of [Pt(barb-κN)2(bpy-κN,N’)] (4). The 
procedure and quantities of the reactants for the preparation of 
4 were the same as for 3 with [PtCl2(bpy)] replacing 
[PdCl2(bpy)]. Yellow prisms of 4 were formed by slow 
evaporation of the DMSO solution (yield: 0.611 g, 72%, mp 
(decomp.)  372–375 °C). Anal. calc. for C26H36N6O9Pt (%): C, 
40.47; H, 4.70; N, 10.89. Found: C, 40.77; H, 5.95; N, 11.03. 
IR (KBr, ν/cm–1) 3179w (NH-barb), 3085w (arom. CH), 3045w 
(arom. CH), 2971m (aliph. CH), 2936w (aliph. CH), 2877w 
(aliph. CH), 1716m (CO), 1688s (CO), 1641vs (CO), 1607s 
(CN), 1452m (CC), 1400s, 1363vs, 1322vs, 1242m, 1028m, 
953w, 1162w,  770m, 546w. 1H NMR (400 MHz, DMSO-d6; 
Me4Si): δ (ppm) 10.82 (s, 2H, NH-barb), 8.72-8.55 (m, 2H, 
3J(HH) = 8.0 Hz, H6, H6'-bpy), 8.53-8.51 (d, 2H, 3J(HH) = 7.6 
Hz, H3, H3’-bpy), 8.51-8.47 (m, 2H, 3J(HH) = 7.2 Hz, H4, H4'-
bpy), 7.90-7.76 (m, 2H, 3J(HH) = 7.2 Hz, H5, H5'-bpy), 1.75-
1.63 (q, 3J(HH) = 7.2 Hz, 8H, CH2-barb), 0.75-0.47 (tt, 3J(HH) 
= 7.2 Hz, 12H, CH3-barb). 13C NMR (100 MHz, DMSO-d6; 
Me4Si): δ 178.2, 174.5, 156.2 CO barb, 155.1 C2-bpy, 149.6 
C6-bpy, 141.8 C4-bpy, 127.8 C3-bpy, 124.5 C5-bpy, 56.2 
CEt2-barb, 32.1 CH2-barb, 10.0 CH3-barb. UV λmax (MeOH)/nm 
247, 308 and 321 (ε/dm3 mol–1 cm–1 26000, 9600 and 12000). 
Molar conductivity, Molar conductivity, ΛM (1×10−3 M, 
MeOH) 14 S cm2 mol−1 (nonelectrolyte) and ΛM (1×10−3 M, 
DMSO) 3 S cm2 mol−1 (nonelectrolyte). ESI-MS (m/z, MeOH): 
740.2, [M+Na]+ (calc. 740.6), 534.1 [M–barb]+ (calc. 534.5). 
 Synthesis of [Pd(barb-κN)2(dpya-κN,N’)] (5). The 
preparation method for 5 was the same as described for 3, using 
dpya instead of bpy. Yellow crystals were collected by filtration 
(yield: 0.585 g, 91%, mp (decomp.) 292–296 °C). Anal. calc. 
for C26H31N7O6Pd (%): C, 48.91; H, 4.90; N, 15.21. Found: C, 
48.64; H, 4.85; N, 15.07. IR (KBr, ν/cm-1) 3306w (NH-dpya), 
3205m (NH-barb), 3145w (arom. CH), 3086w (arom. CH), 
2963w (aliph. CH), 2936w (aliph. CH), 2878(w), 1720m (CO), 
1674s (CO), 1637vs (CO), 1589m (CN), 1517w, 1483s (CC), 
1436m, 1407s, 1363m, 1316s, 1242m, 1163w, 1038w, 958w, 
772m, 541w. 1H NMR (400 MHz, DMSO-d6; Me4Si): δ (ppm) 
10.63 (s, 2H, NH-barb), 9.65 (s, H, NH-dpya), 8.18-7.96 (dd, 
2H, 3J(HH) = 7.2 Hz, H6, H6'-dpya), 7.90-7.69 (td, 2H, 3J(HH) = 
8.4 Hz, H4, H4’-dpya), 7.64-7.26 (m, 2H, 3J(HH) = 8.4 Hz, H3, 
H3'-dpya), 7.03-6.81 (tt, 2H, 3J(HH) = 7.2 Hz, H5, H5'-dpya), 
1.78-1.50 (m, 3J(HH) = 7.2 Hz, 8H, CH2-barb), 0.72-0.47 (tt, 
3J(HH) = 7.6 Hz, 12H, CH3-barb). 13C NMR (100 MHz, 
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DMSO-d6; Me4Si): δ 177.7, 174.7, 154.6 CO barb, 154.3 C2-
dpya, 147.3 C6-dpya, 137.4 C4-dpya, 115.7 C5-dpya, 111.6 
C3-dpya, 55.8 CEt2-barb, 31.8 CH2-barb, 9.1 CH3-barb. UV 
λmax (MeOH)/nm 302 and 317 (ε/dm3 mol–1 cm–1 17200 and 
14000). Molar conductivity, ΛM (1×10−3 M, MeOH) 21 S cm2 
mol−1 (nonelectrolyte) and ΛM (1×10−3 M, DMSO) 12 S cm2 
mol−1 (nonelectrolyte). ESI-MS (m/z, MeOH): 666.1, [M+Na]+ 
(calc.: 666.9), 460.1 [M–barb]+ (calc.: 460.8). 
 Synthesis of [Pt(dpya-κN,N’)2][Ag(barb-κN)2]2·4H2O (6). 
The procedure for the preparation of 6 were the same as for 4 
with dpya replacing bpy. The resulting yellow solid was 
recrystallized from a mixture of MeOH, MeCN and water 
(1:1:1) (yield: 0.945 g, 85%, mp (decomp.)  315–318 °C). Anal. 
calc. for C54H76Ag2N14O16Pt (%): C, 40.41; H, 4.60; N, 12.51. 
Found: C, 40.18; H, 4.55; N, 12.57. IR (KBr, ν/cm–1) 3457bs 
(OH), 3416bs (OH), 3318w (NH-dpya), 3184m (NH-barb), 
3065w (arom. CH), 2971m (arom. CH), 2934w (aliph. CH), 
2872w (aliph. CH), 1693m (CO), 1665s (CO), 1642s (CO), 
1567m (CN), 1534s, 1480vs (CC), 1439vs, 1363m, 1314s, 
1267m, 1238m, 1164w, 1029w, 845w, 777m, 543w. 1H NMR 
(400 MHz, DMSO-d6; Me4Si): δ (ppm) 10.63 (s, 4H, NH-barb), 
9.65 (s, 2H, NH-dpya), 8.19-7.94 (dd, 4H, 3J(HH) = 7.2 Hz, H6, 
H6'-dpya), 7.86-7.69 (td, 4H, 3J(HH) = 8.4 Hz, H4, H4’-dpya), 
7.64-7.25 (tt, 4H, 3J(HH) = 8.4 Hz, H3, H3'-dpya), 7.01-6.81 (tt, 
4H, 3J(HH) = 7.2 Hz, H5, H5'-dpya), 1.79-1.47 (m, 3J(HH) = 7.2 
Hz, 16H, CH2-barb), 0.72-0.50 (tt, 3J(HH) = 7.6 Hz, 24H, CH3-
barb). 13C NMR (100 MHz, DMSO-d6; Me4Si): δ 178.9, 154.5, 
154.2 CO barb, 149.7 C2-dpya, 147.3 C6-dpya, 137.4 C4-dpya, 
115.7 C5-dpya, 111.6 C3-dpya, 57.3 CEt2-barb, 31.8 CH2-barb, 
9.1 CH3-barb. UV λmax (MeOH)/nm 251 (ε/dm3 mol–1 cm–1 
13600). Molar conductivity, ΛM (1×10−3 M, MeOH) 171 S cm2 
mol−1 (1:2 electrolyte) and ΛM (1×10−3 M, DMSO) 74 S cm2 
mol−1 (1:2 electrolyte). ESI-MS (m/z, MeOH): 536.1, 
[Pt(dpya)2–H]+ (calc. 536.4), 520.1 [Ag(barb)2+2Na]+ (calc. 
520.3). 
Stability assays 
The stability of the complexes was performed in MeOH and a 
saline solution (0.9% NaCl). 1 mL of 1 mM test compounds in 
MeOH and the saline solution (stock solution 10 mM in 
MeOH) was incubated at room temperature and 37°C, 
respectively. An Agilent 1200 HPLC system was used for 
determination of the complexes at 0 and 24-h intervals. 
Chromatographic separations were carried out using an 
XBridge C18 (4.6 x 250mm, 3.5 mm) column from Waters. 
The mobile phase consists of water (solvent A) and acetonitrile 
(solvent B). Gradient conditions are as follows: 0-8 min 30% B, 
8-19 min 70% B, 16-19 min 90% B, 18-20 min 30% B, and the 
total run time is 20 min. Flow rate was 0.75 mL/min and 
injection volume was 20 µL. Data acquisition and 
preprocessing was done with Chemstation for LC (Agilent). 
The disappearance of the complexes over time was monitored 
at 254 nm and expressed as remaining percentage compared to 
the initial amount.  
 
X-ray crystallography 
The intensity data for 1 and 6 were collected with a STOE 
IPDS 2 diffractometer, while those for 3–5 were obtained using 
a Nonius KappaCCD diffractometer using Mo Kα radiation 
(0.71073 Å) in each case. The structures were solved by direct 
methods and refined against |F|2 with the SHELX-97 
program.101 Compounds 1, and 3–5 contain highly disordered 
DMSO molecules, which were eliminated from the refinement 
of these structures by means of the SQUEEZE subroutine of 
PLATON102 and the hkl intensities were modified accordingly. 
All non-hydrogen atoms were found from the difference 
Fourier map and refined anisotropically, while all hydrogen 
atoms were placed and refined using a riding model. CCDC 
1034029 (1), 1034030 (3), 1034031(4), 1034032 (5) and 
1034033 (6) contain the supplementary crystallographic data 
for this paper. These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif (or from the Cambridge 
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 
1EZ, UK; fax: (+44)1223-336-033; or deposit@ccdc.cam.uk). 
DNA binding experiments 
Stock solutions of metal complexes were prepared using MeOH 
and then diluting them suitably with Tris-HCl buffer to the 
required concentrations for all the experiments. Absorption 
spectral titration experiments were performed by maintaining a 
constant concentration of the complex (25 μM) and varying the 
FS-DNA concentration (0-50 μM). The UV-Vis spectra of the 
FS-DNA solutions in the presence of each complex was 
scanned against the Tris-HCl buffer solution in the wavelength 
range from 200 to 500 nm. 
 In the ethidium bromide (EB) fluorescence quenching 
experiments, DNA was pretreated with EB in the ratio [NP/EB] 
= 10 in Tris-HCl buffer and then, the complexes ranging from 
12.5 to 100 μM were added to this solution. All solutions were 
allowed to equilibrate thermally at 20 ºC for about 30 min 
before measurements. The fluorescence spectra of the solutions 
were recorded in the range of 500-750 nm at λex = 295 nm.  
 Competitive binding between Hoechst 33258 and the 
complexes was studied by measuring fluorescence intensity of 
Hoechst 33258-DNA solutions in the ratio [NP/Hoechst 33258] 
= 10 in the absence and presence of the compounds (12.5-100 
μM) in Tris-HCl buffer. The fluorescence spectra of these 
solutions were recorded in the range of 400-650 nm at λex = 351 
nm.  
 For viscosity measurements, an Ubbelodhe viscometer was 
immersed in a thermostatic water-bath at 20.0 ºC. The 
concentration of FS-DNA in Tris-HCl buffer was 25 μM and 
the viscosity of the FS-DNA solutions were measured in the 
presence of increasing amounts of the complexes (12.5-50 μM). 
Flow time was measured with a digital stopwatch and each 
sample was measured three times, then an average flow time 
was calculated. Viscosity values were calculated from the 
observed flow time of DNA-containing solutions (t) corrected 
for the flow time of buffer alone (t0), η = t – t0.  
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 Thermal denaturation measurements were performed with a 
Perkin-Elmer Lambda 35 UV/Vis spectrophotometer equipped 
with a Peltier temperature-controlled sample cell. The 
temperature of FS-DNA (100 μM) in the absence and presence 
of the complexes (50 μM) were carried out by monitoring the 
absorbance at 260 nm in the temperature range of 25–95 °C 
with a heating rate of 2.5 °C min−1 in Tris-HCl buffer. The 
melting temperature (Tm) values were determined graphically 
from the plot of relative absorbance (A/A25) versus 
temperature, where A is the observed absorbance and A25 is the 
absorbance at 25 ºC. 
Cellular uptake studies 
To investigate cellular uptake and intracellular distribution of 
complexes 1, 2 and 5, DU-145 cells were exposed to 50 µM of 
each complex at 37 ˚C for 1 h. Treatments were stopped by 
removing the incubation medium and adding cold PBS.  Then, 
cells were washed with cold phosphate-buffered saline (PBS) 
twice, tyripsinized, resuspended in medium (1:5 v/v) and 
counted using a hemocytometer. Different fractions of cells 
(cytosol, nucleus, membrane/particulate and cytoskeletal 
fractions) were isolated from these cell suspensions using 
FractionPREP cell fractionation kit (Biovision) according to the 
provided protocol. The fractions were digested with 65% HNO3 
(3 mL) at 70 °C for 3 h and then diluted with ultra pure water to 
a final volume of 5 mL. The Pd and Pt contents in the different 
fractions were measured using Agilent 7500 Series ICP-MS 
system with 114In and 209Bi used as internal standards. The 
metal contents obtained in ppb units were then expressed as 
ng/106 cells. 
DNA cleavage experiments 
 Gel electrophoresis. The cleavage of pUC19 plasmid DNA 
by complexes 1–6 was monitored using agarose gel 
electrophoresis at room temperature. The gel electrophoresis 
experiments were performed by incubation of the samples 
containing 10 μM plasmid DNA and metal complex (0.5-50 
μM) in 50 mM Tris-HCl/18 mM NaCl buffer (pH 7.2) at 37 ºC 
for 24 h. A dye solution (bromophenol blue 0.05%, sucrose 
40%, 0,5% sodium lauryl sulfate (SDS) and 0.1 M EDTA) was 
added to the reaction mixture and then, the samples were 
electrophoresed for 1 h at 90 V on 1% agarose gel using 0.5X 
TBE buffer (pH 8.0). The gel was then stained using 1 μg cm−3 
EB and photographed under UV light.  
 Restriction enzyme inhibition. The restriction enzyme 
inhibition assay was carried out to know the sequence-specific 
binding and evaluation of enzyme inhibition by complexes. 
pUC19 (10 µM) plasmid was incubated with 1 or 10 µM 
concentration of each of the complexes in DMSO at 37 ºC in 50 
mM Tris–HCl/18 mM NaCl buffer (pH 7.2) for 24 h for 
complexes 3–6 and 30 min for complexes 1 and 2. Then these 
solutions were incubated separately with HindIII and BamHI (2 
units) for 1 h under similar conditions. The results of incubation 
were obtained from 1.5 % (w/v) agarose gel electrophoresis in 
1x TAE buffer. The gel was then stained using 1 μg cm−3 EB 
and photographed under UV light.  
Molecular docking 
Molecular docking studies were performed using 
Autodock/Vina program.103 The PDB format of the complexes 
was obtained by converting its CIF file using Mercury software. 
The molecular geometry of complex 2 was fully optimized by 
DFT using the hybrid B3LYP approach and the LANL2DZ 
basis set.104 Then, the structural parameters for 2 were 
converted to the PDB file. Two structures of B-DNA (1DNE, 
d(CGCGATATCGCG)2 and 1DSC, d(GAAGCTTC)2) were 
selected from the Protein Data Bank. The water molecules and 
the ligands were removed from 1DNE and 1DSC before 
performing docking calculations. The binding site was centered 
on the DNA and a grid box was created with 60 × 60 × 60 
points and a 0.375 Å grid spacing in which almost the entire 
macromolecules were involved.  For each docking calculation, 
20 different posses were requested within the energy range of 2 
kcal mol–1. All other parameters were kept at their default 
values.  
Antioxidant activity 
The radical-scavenging activity of the complexes was measured 
using 2,2-diphenyl-2-picryl-hydrazyl (DPPH).105,106 The 
solutions of the complexes in MeOH at different concentrations 
was mixed with a solution of DPPH in MeOH (0.1 mM, 2 mL) 
and the final volume was made up to 5 mL with double distilled 
water. The resulting solutions were stirred rigorously. The 
DPPH solution in methanol was used as a control and MeOH 
alone was used as a blank. The solutions were incubated at 37 
ºC for 30 min in dark. The absorbance of the solutions was 
measured at 517 nm. 
 The total antioxidant activity of the complexes was studied 
using the 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
(ABTS) cationic radical.107 ABTS was dissolved in water to a 2 
mM concentration and the ABTS•+ radical was produced by 
adding 0.2 mM potassium persulfate into the ABST solution. 
The resulting mixture was kept in the dark at room temperature 
for 12-16 h before use. The ABTS solution was diluted with 
MeOH to give an absorbance of 0.70 at 743 nm. The various 
concentrations of the solutions of the complexes in MeOH were 
added to 2 mL of the diluted ABTS cationic radical solution 
and the final volume was made up to 5 mL with double distilled 
water. Then, the absorbance reading was taken against MeOH 
at 15 min after the initial mixing.  
 All of the tests were run in triplicate, and the percentage of 
activity was calculated by using % radical activity = [(A0 – 
Ac)/A0] x 100, where A0 and Ac represent the absorbance in the 
absence and presence of the complexes, respectively. Ascorbic 
acid and butylated hydroxytoluene (BHT) were used as 
standards for the two tests. The 50% activity (IC50) was 
calculated using the percentage of activity. 
Cytotoxic activity assay (MTT) 
Stock concentrations of cisplatin, carboplatin, oxaliplatin and 
complexes 1–6 were prepared in DMSO, while their final 
concentrations were prepared in the culture medium. For each 
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complex and anticancer drug, seven different concentrations 
ranging from 3.12 to 300 μM were used. The results 
represented the mean of two or three independent experiments 
run in triplicates.  
 Human carcinoma cell lines of MCF-7 (breast), HT-29 
(colon) and DU-145 (prostate) were used, while PNT-1A 
(human prostatic epithelial cell) was used as normal cell.  
 The colon cell line (HT-29) was cultured in McCoy’s 
medium supplemented with penicillin G (100 U/mL), 
streptomycin (100 µg/mL), L-glutamine, and 10% fetal calf 
serum at 37 °C in a humidified atmosphere containing 5% CO2. 
The other cell cell lines were cultured in RPMI medium 
supplemented with penicillin G (100 U/mL), streptomycin (100 
µg/mL), L-glutamine, and 10% fetal calf serum at 37 °C in a 
humidified atmosphere containing 5% CO2.  
 The MTT cell viability assay [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide] was performed as follows. 
The cells were seeded in 200 µL culture medium in triplicates 
at a density of 5x103 cells per well in a 96-well plate. Cells 
were treated with different concentrations of each complex for 
48 h. Untreated cells were used as positive control for viability. 
MTT was supplied as a stock solution (5 mg/mL in PBS, pH 
7.2) and sterile-filtered. At the end of the treatment period, 20 
µL of MTT solution was added to each well. Following 4 h of 
incubation, 100 µL of solubilizing buffer (10% SDS dissolved 
in 0.01 N HCl) was added to each well. After 16 h incubation, 
the absorbance was determined by an ELISA plate reader at 
594 nm as a read-out for cell viability. The cytotoxicity is 
mainly determined by the IC50 value (the dose inhibiting 50% 
of growth with respect to viability control) of each metal 
complex. 
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